TrialBritish journal of cancer2019

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Vincenzo Mazzaferro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.